prima - one of the best stocks on asx, page-7

Here's just a snippet....

The global market size of ovarian cancer is estimated to grow to US$3.6b
by 2010
Each year 73,000 women are diagnosed with ovarian cancer in the US,
Europe, Australia and Japan. 318,000 globally
Of this number, only 10% survive beyond 5 years
A maintenance style treatment like CVac would be the first of its type in
the market and would initially aim to take a conservative 10-25% of this
Cell Therapy A new paradigm
for the treatment of cancer
ovarian cancer treatment market
76% of patients relapse within a year of chemotherapy
Non-toxic nature of CVac creates a no-brainer for the oncologist
A conservative 10% market share equates to approximately US$360m
p.a. Wall St analysts of DNDN suggest market size could be greater than
US$1.5Bn per indication
CVac also has further indications across a number of other cancers